NeuroSense Therapeutics (NRSN) Shares Outstanding (2020 - 2025)

NeuroSense Therapeutics has reported Shares Outstanding (Entity) for 6 years, with the latest figure at $637.0 million in Q4 2025.

• Quarterly Shares Outstanding (Entity) rose 36.98% year-over-year to $637.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $637.0 million (up 36.98% YoY) and the FY2025 annual result came in at $637.0 million, up 36.98% from the prior year.
• Shares Outstanding (Entity) held at $637.0 million in Q4 2025 per NRSN's latest filing, from $635.1 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $637.0 million in Q4 2025 and troughed at $16774.0 in Q2 2024.
• A 5-year average of $316.8 million and a median of $287.6 million in 2022 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Entity) slumped 100.0% in 2024, then soared 3785915.41% in 2025.
• Over 5 years, Shares Outstanding (Entity) stood at $156.1 million in 2021, then surged by 84.27% to $287.6 million in 2022, then increased by 18.41% to $340.6 million in 2023, then surged by 36.55% to $465.1 million in 2024, then surged by 36.98% to $637.0 million in 2025.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $637.0 million, $635.1 million, and $465.1 million for Q4 2025, Q2 2025, and Q4 2024 respectively.